Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Educ Prim Care ; 31(6): 365-370, 2020 11.
Article in English | MEDLINE | ID: mdl-32862789

ABSTRACT

Purpose: Nowadays chronicity is one of the most frequent aspects of care doctors have to deal with. Students need to know and learn clinical, relational, social and managerial elements of chronicity and changes that disease causes in patients, families and doctors themselves. Methods: Students are supervised by a family doctor, in taking care of 'their' patient and of his/her family. They are asked to keep an updated diary, participate in the periodical revision of the medical history and write an end-report. Two focus groups were conducted, adopting a constructive qualitative approach in order to analyse results. Results: The focus groups and the SWOT analysis show common themes such as innovative learning and multidisciplinary approach. Clinical evolution of the disease, mental and body changes and the diagnostic and therapeutic future planning were also revealed. Conclusions: The main goal of this innovation was understanding the importance of a continuous clinical relationship and of the role of the doctor as 'therapy itself'. The project was demonstrated to be able to teach the future physicians how to practice more empathetic medicine and to improve the skills needed in a complex relational environment including that of chronic disease.


Subject(s)
Chronic Disease , Continuity of Patient Care , Education, Medical, Undergraduate/methods , Family Practice/education , Family Practice/methods , Focus Groups , Humans , Italy , Learning , Students, Medical/psychology
2.
J Clin Invest ; 108(4): 619-23, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11518736

ABSTRACT

Hemochromatosis is a progressive iron overload disorder that is prevalent among individuals of European descent. It is usually inherited in an autosomal-recessive pattern and associated with missense mutations in HFE, an atypical major histocompatibility class I gene. Recently, we described a large family with autosomal-dominant hemochromatosis not linked to HFE and distinguished by early iron accumulation in reticuloendothelial cells. Through analysis of a large pedigree, we have determined that this disease maps to 2q32. The gene encoding ferroportin (SLC11A3), a transmembrane iron export protein, lies within a candidate interval defined by highly significant lod scores. We show that the iron-loading phenotype in autosomal-dominant hemochromatosis is associated with a nonconservative missense mutation in the ferroportin gene. This missense mutation, converting alanine to aspartic acid at residue 77 (A77D), was not seen in samples from 100 unaffected control individuals. We propose that partial loss of ferroportin function leads to an imbalance in iron distribution and a consequent increase in tissue iron accumulation.


Subject(s)
Amino Acid Substitution , Carrier Proteins/genetics , Cation Transport Proteins , Chromosomes, Human, Pair 2/genetics , Genes, Dominant , Hemochromatosis/genetics , Membrane Proteins/genetics , Mononuclear Phagocyte System/metabolism , Mutation, Missense , Animals , Carrier Proteins/physiology , Codon/genetics , Exons/genetics , Female , Genetic Heterogeneity , HLA Antigens/genetics , Hemochromatosis/epidemiology , Hemochromatosis Protein , Histocompatibility Antigens Class I/genetics , Homeostasis , Humans , Iron/metabolism , Iron Overload/genetics , Iron Overload/metabolism , Italy/epidemiology , Lod Score , Male , Membrane Proteins/deficiency , Membrane Proteins/physiology , Mice , Pedigree , Phenotype , Receptors, Transferrin/genetics
3.
J Hepatol ; 34(4): 523-8, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11394651

ABSTRACT

BACKGROUND/AIMS: The actual prevalence of the main hemochromatosis (HFE) mutations in the Italian adult population and their phenotypic expression have not yet been established. This information is key to advocate a mass-screening program. METHODS: Two thousand one hundred adults were tested for the C282Y/H63D HFE gene mutations by an automated genotyping assay as well as transferrin saturation (TS) and serum ferritin levels. RESULTS: No homozygotes for the C282Y mutation were found. Heterozygosity for the C282Y mutation was 3.1%, while heterozygosity and homozygosity for the H63D mutation were 21.5% and 2.5%, respectively. TS was significantly higher in C282Y heterozygotes and H63D homozygotes as compared to wild-type individuals (P < 0.01). Interestingly, of the HFE wild-type subjects 5.9% had a TS value above the 45% threshold. CONCLUSIONS: This study shows that (i) the predicted prevalence for C282Y homozygosity in Italy is 1:3900; (ii) the C282Y/H63D wild-type population has an increased baseline of iron parameters possibly due to genetic factors not linked to the C282Y/H63D mutations; (iii) since in the latter population the actual tissue iron burden cannot be assessed, phenotypic (TS) screening in Italy is not recommended until the true prevalence of all mutations in the HFE gene and in other hemochromatosis genes will be established.


Subject(s)
Gene Expression , HLA Antigens/genetics , Hemochromatosis/genetics , Histocompatibility Antigens Class I/genetics , Membrane Proteins , Mutation , Adult , Female , Gene Frequency , Hemochromatosis Protein , Heterozygote , Homozygote , Humans , Italy , Male , Middle Aged , Reference Values , Transferrin/analysis
4.
Pharmacology ; 62(2): 107-12, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11174081

ABSTRACT

Complexation of ursodeoxycholic acid (UDCA) with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) improves the water solubility and the dissolution rate of UDCA and may therefore increase its bioavailability. We compared the amount and the rate of biliary excretion of UDCA and biliary lipid secretion after a single oral administration of UDCA in 3 different pharmaceutical formulations [UDCA-HPbetaCD ('urso-beta-cyclodextrin'), UDCA suspension and UDCA capsule] at 3 different dosages each, in 11 groups (2 control groups) of bile fistula rats. UDCA excretion increased with an increase in dose, biliary UDCA recovery and peak secretion were significantly higher after administration of UDCA-HPbetaCD than after UDCA in suspension or capsule. This enhancement of biliary excretion may achieve greater UDCA enrichment in the bile acid pool than conventional pharmaceutical UDCA formulations, this giving to UDCA-HPbetaCD a considerable therapeutical potential.


Subject(s)
Bile/metabolism , Cyclodextrins/pharmacokinetics , Ursodeoxycholic Acid/pharmacokinetics , beta-Cyclodextrins , 2-Hydroxypropyl-beta-cyclodextrin , Administration, Oral , Animals , Biliary Fistula , Biological Availability , Chemistry, Pharmaceutical , Drug Combinations , Male , Rats , Rats, Sprague-Dawley
5.
Blood ; 96(3): 1125-9, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10910932

ABSTRACT

Hereditary hemochromatosis (HC) is one of the most common single-gene hereditary diseases. A phenotypic hallmark of HC is low iron in reticuloendothelial cells in spite of body iron overload. Most patients with HC have the same mutation, a change of cysteine at position 282 to tyrosine (C282Y) in the HFE protein. The role of HFE in iron metabolism and the basis for the phenotypic abnormalities of HC are not understood. To clarify the role of HFE in the phenotypic expression of HC, we studied monocytes-macrophages from subjects carrying the C282Y mutation in the HFE protein and clinically expressing HC and transfected them with wild-type HFE by using an attenuated Salmonella typhimurium strain as a gene carrier. The Salmonella system allowed us to deliver genes of interest specifically to monocytes-macrophages with high transduction efficiency. The accumulation of (55)Fe delivered by (55)Fe-Tf was significantly lower in macrophages from patients with HC than from controls expressing wild-type HFE. Transfection of HC macrophages with the HFE gene resulted in a high level of expression of HFE protein at the cell surface. The accumulation of (55)Fe delivered by (55)Fe-Tf was raised by 40% to 60%, and this was reflected by an increase in the (55)Fe-ferritin pool within the HFE-transfected cells. These results suggest that the iron-deficient phenotype of HC macrophages is a direct effect of the HFE mutation, and they demonstrate a role for HFE in the accumulation of iron in these cells.


Subject(s)
Gene Transfer Techniques , Genetic Vectors , HLA Antigens/genetics , HLA Antigens/metabolism , Hemochromatosis/genetics , Hemochromatosis/metabolism , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/metabolism , Macrophages/metabolism , Membrane Proteins , Monocytes/metabolism , Salmonella typhimurium , Cells, Cultured , Genetic Therapy , Hemochromatosis/therapy , Hemochromatosis Protein , Humans , Iron/metabolism , Transferrin/metabolism
6.
J Bioenerg Biomembr ; 32(2): 175-82, 2000 Apr.
Article in English | MEDLINE | ID: mdl-11768750

ABSTRACT

Hepatic iron toxicity because of iron overload seems to be mediated by lipid peroxidation of biological membranes and the associated organelle dysfunctions. However, the basic mechanisms underlying this process in vivo are still little understood. Gerbils were dosed with weekly injections of iron-dextran alone or in combination with sylibin, a well-known antioxidant, by gavage for 8 weeks. A strict correlation was found between lipid peroxidation and the level of desferrioxamine chelatable iron pool. A consequent derangement in the mitochondrial energy-transducing capability, resulting from a reduction in the respiratory chain enzyme activities, occurred. These irreversible oxidative anomalies brought about a dramatic drop in tissue ATP level. The mitochondrial oxidative derangement was associated with the development of fibrosis in the hepatic tissue. Silybin administration significantly reduced both functional anomalies and the fibrotic process by chelating desferrioxamine chelatable iron.


Subject(s)
Antioxidants/pharmacology , Iron Overload/prevention & control , Iron/adverse effects , Liver Cirrhosis/prevention & control , Mitochondria/drug effects , Oxidants/adverse effects , Silymarin/pharmacology , Adenosine Triphosphate/metabolism , Animals , Disease Models, Animal , Gerbillinae , Iron/metabolism , Iron Overload/metabolism , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/metabolism , Lipid Peroxidation , Liver/metabolism , Liver Cirrhosis/chemically induced , Liver Cirrhosis/etiology , Liver Cirrhosis/metabolism , Male , Mitochondria/metabolism , Mitochondria/physiology , Oxidants/metabolism , Oxidative Stress
7.
N Engl J Med ; 341(10): 725-32, 1999 Sep 02.
Article in English | MEDLINE | ID: mdl-10471458

ABSTRACT

BACKGROUND AND METHODS: Hereditary hemochromatosis in adults is usually characterized by mutations in the HFE gene on the short arm of chromosome 6. Most patients have a substitution of tyrosine for cysteine at position 282 (C282Y). We studied a large family from Italy that includes persons who have a hereditary iron-overload condition indistinguishable from hemochromatosis but without apparent pathogenic mutations in the HFE gene. We performed biochemical, histologic, and genetic studies of 53 living members of the family, including microsatellite analysis of chromosome 6 and direct sequencing of the HFE gene. RESULTS: Of the 53 family members, 15 had abnormal serum ferritin levels, values for transferrin saturation that were higher than 50 percent, or both. Thirteen of the 15 had elevated body iron levels, diagnosed on the basis of the clinical evaluation and liver biopsy, and underwent iron-removal therapy. The other two, both children, did not undergo liver biopsy or iron-removal therapy. None of the 15 members had the C282Y mutation of the HFE gene; 5 of the 15 (as well as 5 healthy relatives) had another mutation of this gene, a substitution of aspartate for histidine at position 63, but none were homozygous for it. No other mutations were found after sequencing of the entire HFE gene for all family members. Microsatellite analysis showed no linkage of the hemochromatosis phenotype with the short arm of chromosome 6, the site of the HFE gene. CONCLUSIONS: Hereditary hemochromatosis can occur in adults who do not have pathogenic mutations in the hemochromatosis gene.


Subject(s)
HLA Antigens/genetics , Hemochromatosis/genetics , Histocompatibility Antigens Class I/genetics , Membrane Proteins , Adolescent , Adult , Child , Chromosomes, Human, Pair 6/genetics , Female , Ferritins/blood , Genetic Linkage , Hemochromatosis/blood , Hemochromatosis/pathology , Hemochromatosis Protein , Humans , Iron/analysis , Italy , Liver/chemistry , Male , Microsatellite Repeats , Middle Aged , Mutation , Pedigree , Transferrin/analysis
8.
Life Sci ; 63(14): PL213-9, 1998.
Article in English | MEDLINE | ID: mdl-9771919

ABSTRACT

Iron Regulatory Proteins (IRPs), by modulating expression of ferritin, which stores excess iron in a non toxic form, and transferrin receptor, which controls iron uptake, are the main controller of cellular iron metabolism. During inflammation, modification of IRP activity may affect iron availability, free radical generation and cytokine gene response in inflammatory cells. In the present study we tested the effect of inflammatory stimuli on IRP function in a human monocytic-macrophagic cell line and the possibility of interfering with these pathways by using an antiinflammatory compound, diacerhein (DAR). IRP activity was enhanced by interferon gamma/lipopolysaccarhide (IFN/LPS), and this effect was consistently counteracted by increasing concentrations of DAR. No direct effect of DAR on IRP activity was found in vitro. However, in vivo, similar IRP activation was achieved by exposing cells to nitric oxide (NO) donors and the LPS/IFN-induced activation of IRP was reversed by NO inhibitors. Interestingly, NO-induced IRP activation was efficiently blocked by DAR. These data show for the first time that a clinically useful antiinflammatory compound, DAR, interferes with IRP activation by NO in inflammed human cells.


Subject(s)
Anthraquinones/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Inflammation/metabolism , Iron-Sulfur Proteins/antagonists & inhibitors , Monocytes/drug effects , RNA-Binding Proteins/antagonists & inhibitors , Cell Line , Humans , Iron-Regulatory Proteins , Nitric Oxide/physiology
9.
Hepatology ; 27(6): 1611-22, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9620335

ABSTRACT

Oxidant stress plays a key role in hepatic fibrogenesis. This study was undertaken to assess whether, during iron overload-associated liver fibrosis in vivo, oxidant stress occurs in hepatic stellate cells (HSC) during active fibrogenesis. Gerbils were treated with iron-dextran, and, after hepatic fibrosis developed, livers were subjected to various combination of in situ hybridization and immunocytochemistry analyses. In iron-treated animals, no specific accumulation of ferritin protein was found in collagen mRNA-expressing cells. Moreover, the activity of the iron regulatory protein, the main sensor of cellular iron status, was unchanged in HSC from iron-treated animals. Although a significant amount of malondialdehyde-protein adducts was detected in gerbil liver during fibrogenesis, accumulation of these lipid peroxidation by-products was restricted to iron-laden cells adjacent to activated HSC. In cultured gerbil HSC, iron, aldehydes, and other pro-oxidants were able to enhance the expression of an oxidant stress-responsive gene, heme oxygenase (HO), with no change in collagen mRNA accumulation. In keeping with these findings, we found that, in vivo, activation of HO gene was present in iron-filled nonparenchymal cell aggregates, but absent in HSC. In conclusion, the data indicate that during iron overload-associated fibrogenesis, HSC are not directly subjected to oxidant stress, but are likely to be activated by paracrine signals arising in neighboring cells.


Subject(s)
Iron Overload/metabolism , Iron Overload/pathology , Liver Cirrhosis, Experimental/metabolism , Liver Cirrhosis, Experimental/pathology , Liver/metabolism , Liver/pathology , Animals , Cells, Cultured , Gerbillinae , Iron/metabolism , Kupffer Cells/metabolism , Kupffer Cells/pathology , Male , Oxidative Stress
10.
Am J Pathol ; 152(5): 1319-26, 1998 May.
Article in English | MEDLINE | ID: mdl-9588900

ABSTRACT

In vitro and in vivo studies indicate that oxidant stress is implicated in liver fibrogenesis. However, it is still unknown whether, in vivo, oxidant stress directly affects the hepatic cells responsible for fibrogenesis, ie, the hepatic stellate cells (HSCs). This study was aimed at answering this question by assessing the temporal and spatial relationships between oxidant stress and activation of HSCs in an in vivo model of oxidant-stress-associated fibrogenesis. To this purpose, rats were treated with carbon tetrachloride (CCl4) and livers subjected to in situ perfusion with nitroblue tetrazolium, which, in the presence of superoxide ions, is reduced to an insoluble blue-colored formazan derivative and is readily detectable in the tissue by light microscopy. Moreover, various combinations of in situ hybridization and immunocytochemical analyses were performed. An acute dose of CCl4 caused a transient production of superoxide radicals at 24 hours into pericentral necrotic areas, whereas HSC appearance and expression of collagen mRNA were detectable only at 48 and 72 hours. After chronic CCl4 intoxication, higher levels of oxygen radical production in necrotic areas were detectable along with dramatic and sustained activation of HSCs. However, maximal HSC activation was still delayed as compared with superoxide production. Expression of heme oxygenase, a gene responsive to a variety of oxidant stress mediators, was strongly enhanced by chronic CCl4 administration but remained unchanged in HSCs, both in situ and after isolation of pure HSC fractions from control and CCl4-treated animals. In conclusion, during postnecrotic fibrogenesis, oxidant stress anticipates HSC activation. HSCs do not directly face an oxidant stress while engaged in active fibrogenesis.


Subject(s)
Liver Cirrhosis, Experimental/metabolism , Liver/metabolism , Oxidative Stress , Reactive Oxygen Species/metabolism , Animals , Carbon Tetrachloride/toxicity , Collagen/genetics , Collagen/metabolism , Free Radicals , Heme Oxygenase (Decyclizing)/genetics , Heme Oxygenase (Decyclizing)/metabolism , Immunohistochemistry , In Situ Hybridization , Liver/cytology , Liver Cirrhosis, Experimental/pathology , Male , Necrosis , Nitroblue Tetrazolium , Perfusion , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley
11.
J Endocrinol Invest ; 9(1): 11-4, 1986 Feb.
Article in English | MEDLINE | ID: mdl-3009596

ABSTRACT

Plasma and cerebrospinal fluid (CSF) levels of ACTH, B-lipotropin (B-LPH) and B-endorphin (B-EP) were simultaneously measured in 10 patients with major depression (35-57 yr) with a disease history of 10-34 yr, 7 of them with recurrent episodes, and in 13 age-matched healthy controls. In patients, lumbar puncture was performed after a 10 days drug-free period. Plasma B-EP and B-LPH levels were measured by RIA after silicic acid plasma extraction and Sephadex G-75 column chromatography. Plasma ACTH concentrations were measured by IRMA. For CSF assays the extraction step was avoided. In depressed patients, plasma ACTH (16.2 +/- 6.9 fmol/ml, mean +/- SD), B-LPH (19.8 +/- 8.5) and B-EP (17.8 +/- 7.0) levels were significantly higher (p less than 0.01) than in controls. On the contrary, CSF levels of the three peptides were similar in the two groups. No correlations were found between plasma or CSF concentrations and duration of the disease or severity of the actual episode. These data add further evidence to the independent regulation between central and peripheral POMC-related peptides. They also reduce the possibility that peptides of pituitary origin, directly from the gland or through the peripheral circulation, could penetrate the CSF.


Subject(s)
Depressive Disorder/metabolism , Endorphins/metabolism , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/cerebrospinal fluid , Adult , Depressive Disorder/blood , Depressive Disorder/cerebrospinal fluid , Endorphins/blood , Endorphins/cerebrospinal fluid , Female , Humans , Male , Middle Aged , beta-Endorphin , beta-Lipotropin/blood , beta-Lipotropin/cerebrospinal fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...